KALA BIO expands preferred financing and shareholder authorizations

KALA BIO ( (KALA) ) has issued an update.

On November 24, 2025, KALA BIO completed the first closing of a private placement under a previously disclosed agreement by issuing 900,000 shares of Series AA Convertible Non-Redeemable Preferred Stock at $2.00 per share, raising $1.8 million and creating the potential issuance of 49,500,000 common shares upon conversion. After a series of transfers of purchase rights among investors in December 2025 and January 2026, the company entered a new Securities Purchase Agreement on January 30, 2026, with a group of Series AAA investors and completed a second closing the same day, issuing 2,100,000 shares of Series AAA Preferred Stock at $2.00 per share for $4.2 million in gross proceeds, with each Series AAA share convertible into 420 common shares, or up to 882,000,000 common shares in total; the offering was conducted as a private placement exempt from SEC registration. At its recent Annual Meeting, where 15,489,822 common shares were represented, shareholders elected three Class II directors to terms ending at the 2028 annual meeting, approved executive compensation on an advisory basis, ratified the appointment of HTL International, LLC as independent auditor for 2025, authorized the issuance of common stock upon conversion of the Series AA and Series AAA preferred shares in line with Nasdaq rules, and approved an increase in authorized common stock to 1.5 billion shares as well as a board‑discretionary reverse stock split in a range of 1‑for‑2 to 1‑for‑100, actions that collectively position KALA BIO to significantly expand its equity base and maintain listing compliance while potentially causing substantial dilution to existing shareholders.

The most recent analyst rating on (KALA) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on KALA BIO stock, see the KALA Stock Forecast page.

Spark’s Take on KALA Stock

According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.

The score is driven primarily by very weak financial performance (near-zero revenue, large ongoing losses, negative equity, and substantial cash burn). Technicals are also negative with the stock below key moving averages and a negative MACD. Corporate events are mixed—debt overhang reduction helps, but Nasdaq compliance issues materially elevate risk; valuation metrics provide limited support given negative earnings and no dividend.

To see Spark’s full report on KALA stock, click here.

More about KALA BIO

KALA BIO, Inc. is a publicly traded company that issues common and preferred stock and is listed on Nasdaq, operating within the broader life sciences and biotechnology capital markets where it accesses funding through private placements and manages its shareholder base through annual meetings and corporate governance actions.

Average Trading Volume: 8,108,543

Technical Sentiment Signal: Sell

Current Market Cap: $14.76M

Find detailed analytics on KALA stock on TipRanks’ Stock Analysis page.